As the Biden administration fills key Cabinet positions, its attention must turn to other critical areas of the U.S. government, like appointing a new director of the U.S. Patent and Trademark Office (USPTO). This agency is unusual in the federal government because it operates solely on fees collected by its users and not on taxpayer dollars.
See related First Opinion: Reining in drug patents isn’t a silver bullet against high drug prices
